Multiple myeloma differential diagnosis: Difference between revisions
Jump to navigation
Jump to search
Shyam Patel (talk | contribs) |
Shyam Patel (talk | contribs) No edit summary |
||
Line 22: | Line 22: | ||
| style="padding: 5px 5px; background: #DCDCDC; font-weight: bold; text-align:center;" |'''[[Multiple myeloma]]''' | | style="padding: 5px 5px; background: #DCDCDC; font-weight: bold; text-align:center;" |'''[[Multiple myeloma]]''' | ||
| style="padding: 5px 5px; background: #F5F5F5;" | | | style="padding: 5px 5px; background: #F5F5F5;" | | ||
*Chromosomal aberrations or other genetic insults | |||
*Malignant transformation of plasma cells | *Malignant transformation of plasma cells | ||
*Clonal plasma cell proliferation | *Clonal plasma cell proliferation | ||
Line 31: | Line 32: | ||
| style="padding: 5px 5px; background: #F5F5F5;" | | | style="padding: 5px 5px; background: #F5F5F5;" | | ||
*Induction chemotherapy with bortezomib, lenalidomide, and dexamethasone | *Induction chemotherapy with bortezomib, lenalidomide, and dexamethasone | ||
*Bisphosphonates | *Bisphosphonates | ||
*RANK ligand inhibitors (denosumab) | |||
*Autologous stem cell transplantation | *Autologous stem cell transplantation | ||
|- | |- | ||
| style="padding: 5px 5px; background: #DCDCDC; font-weight: bold; text-align:center;" |'''Osteoporosis''' | | style="padding: 5px 5px; background: #DCDCDC; font-weight: bold; text-align:center;" |'''Osteoporosis''' | ||
| style="padding: 5px 5px; background: #F5F5F5;" | | | style="padding: 5px 5px; background: #F5F5F5;" | | ||
* | *Imbalance between bone resorption and bone formation | ||
* | *Preceded by osteopenia | ||
*Decreased bone mineral density | |||
| style="padding: 5px 5px; background: #F5F5F5;" | | | style="padding: 5px 5px; background: #F5F5F5;" | | ||
* | *Acute musculoskletal pain if [[bone fracture|fracture]] develop | ||
*Severe decrease in [[bone mineral density|BMD]] on dual-energy X-ray absorptiometry (DEXA) test | |||
*T score less than -2.5 on DEXA scan | |||
| style="padding: 5px 5px; background: #F5F5F5;" | | |||
*Calcium and vitamin D supplementation | |||
*Bisphosphonates | |||
*Weight-bearing exercise | |||
*Teriparatide | |||
*RANK ligand inhibitors (denosumab) | |||
|- | |- | ||
| style="padding: 5px 5px; background: #DCDCDC; font-weight: bold; text-align:center;" |'''[[Idiopathic]] transient osteoporosis of [[Hip (anatomy)|hip]]''' | | style="padding: 5px 5px; background: #DCDCDC; font-weight: bold; text-align:center;" |'''[[Idiopathic]] transient osteoporosis of [[Hip (anatomy)|hip]]''' |
Revision as of 01:12, 5 August 2018
Multiple myeloma Microchapters |
Diagnosis |
---|
Treatment |
Case Studies |
Multiple myeloma differential diagnosis On the Web |
American Roentgen Ray Society Images of Multiple myeloma differential diagnosis |
Risk calculators and risk factors for Multiple myeloma differential diagnosis |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Haytham Allaham, M.D. [2]
Overview
Multiple myeloma must be differentiated from monoclonal gammopathy of undetermined significance (MGUS), isolated plasmacytoma of the bone, and extramedullary plasmacytoma.[1]
Differentiating Multiple Myeloma from other Diseases
- The table below summarizes how to differentiate multiple myeloma from other conditions that cause similar presentation:[1]
|
References
- ↑ 1.0 1.1 "Myeloma - SEER Stat Fact Sheets". Retrieved 17 February 2014.